• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill Finish Development and Manufacturing Services

Fill Finish Development and Manufacturing Services

Our fill finish capability caters to a wide range of recombinant protein therapeutics.

With over 10,000 Sq.m of fill finish footprint, we can support filling of a wide range of presentations – vials (liquid and lyophilized), pre-filled syringes and autoinjectors.

Our automated fill finish facility efficiently handles high-accuracy, high-viscosity, low-volume protein filing. End-to-end single-use capability enables for faster change over and assurance of cleaning validation.

Our integrated approach to quality management systems enables greater flexibility and leverage pan - organization experience in managing regulatory audits.

Speak to our experts

Fill Range and Presentation

Fill range is 0.1-100 ml, Vials: 2-100 ml, PFS and auto injector: 0.1-1 ml

Manufacturing Process Flexibility and Formulation

  • Manufacturing process flexibility: peristaltic, rotary piston, end-of-end single-use system, sterile filling
  • Formulation: liquid, lyophilized

Why Aurigene Pharmaceutical Services?

100+ successful regulatory audits

10+K Sq.m facility footprints

300+ tech operations professionals

Operations supported by digital infrastructure

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack